Pancreatic Cancer Research

ResearcherStanford MedicineActive in the last 2 years

Jeffrey Allen Norton

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4762-9466; OpenAlex author ID A5052442796. Sources: OpenAlex.

Their work

Papers
17 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
39
Papers, trials and grants by year

2011: 2 papers · 2012: 2 papers · 2013: none · 2014: 1 paper · 2015: none · 2016: 2 papers · 2017: none · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: none · 2023: 2 papers · 2024: 1 paper · 2025: 3 papers · 2026: 2 papers

Papers 17

  1. NFAT mediates pro-tumorigenic inflammation in cancer-associated fibroblasts in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.celrep.2025.116849↗
  2. Biochemical, Radiographic, or Pathologic Response to Neoadjuvant Chemotherapy in Resected Pancreatic Cancer: Which Is Best? Co-author DOI 10.1097/sla.0000000000006609↗
  3. Disruption of fibroblast MYD88 signaling promotes antitumor immunity in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.celrep.2025.116347↗
  4. Precision Medicine: IL-1RA and Pancreatic Cancer Organoids. Last author DOI 10.3390/biology14060604↗
  5. Correction: Morgan et al. Precision Medicine: IL-1RA and Pancreatic Cancer Organoids. Biology 2025, 14, 604. Last author DOI 10.3390/biology14091133↗
  6. Hematoxylin and Eosin Architecture Uncovers Clinically Divergent Niches in Pancreatic Cancer. Co-author DOI 10.1089/ten.tea.2024.0039↗
  7. Desmoplastic stromal signatures predict patient outcomes in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.xcrm.2023.101248↗
  8. Medical Biology of Cancer-Associated Fibroblasts in Pancreatic Cancer. Last author DOI 10.3390/biology12081044↗
  9. Pancreatic Cancer Associated Fibroblasts (CAF): Under-Explored Target for Pancreatic Cancer Treatment. Co-author DOI 10.3390/cancers12051347↗
  10. Liquid biopsy in pancreatic ductal adenocarcinoma: current status of circulating tumor cells and circulating tumor DNA. Co-author DOI 10.1002/1878-0261.12537↗
  11. Statin and Metformin Use Prolongs Survival in Patients With Resectable Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000000470↗
  12. Pancreatic Cancer Surgical Resection Margins: Molecular Assessment by Mass Spectrometry Imaging. Co-author DOI 10.1371/journal.pmed.1002108↗
  13. Single- versus multifraction stereotactic body radiation therapy for pancreatic adenocarcinoma: outcomes and toxicity. Co-author DOI 10.1016/j.ijrobp.2014.06.066↗
  14. Intensity-modulated radiotherapy for pancreatic adenocarcinoma. Co-author DOI 10.1016/j.ijrobp.2011.09.035↗
  15. Failure to comply with NCCN guidelines for the management of pancreatic cancer compromises outcomes. Co-author DOI 10.1111/j.1477-2574.2012.00496.x↗
  16. Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer. Co-author DOI 10.1016/j.ijrobp.2010.05.006↗
  17. Pattern of lymph node involvement and prognosis in pancreatic adenocarcinoma: direct lymph node invasion has similar survival to node-negative disease. Co-author DOI 10.1097/pas.0b013e318206c37a↗

Closest collaborators

The 25 strongest of 39 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michael Thornton Longaker · 8 shared papers, 2020–2026 · strength 1.80
  2. Annah Grace Morgan · 4 shared papers, 2023–2026 · strength 1.17
  3. Daniel Delitto · 5 shared papers, 2023–2026 · strength 0.95
  4. George A. Poultsides · 8 shared papers, 2012–2026 · strength 0.85
  5. Deshka S. Foster · 5 shared papers, 2020–2026 · strength 0.85
  6. Brendan Christopher Visser · 7 shared papers, 2012–2026 · strength 0.79
  7. Jason L. Guo · 4 shared papers, 2023–2026 · strength 0.70
  8. Daniel Tandel Chang · 6 shared papers, 2011–2026 · strength 0.42
  9. Byrne Lee · 2 shared papers, 2025–2026 · strength 0.42
  10. Amanda Kirane · 2 shared papers, 2025–2026 · strength 0.42
  11. Maria Moozhiyil Korah · 2 shared papers, 2025–2026 · strength 0.39
  12. James Paul Agolia · 2 shared papers, 2025–2026 · strength 0.39
  13. Chuner Guo · 2 shared papers, 2025–2026 · strength 0.39
  14. Teri A. Longacre · 3 shared papers, 2016–2024 · strength 0.37
  15. George Albert Fisher · 4 shared papers, 2011–2026 · strength 0.33
  16. Shamik Mascharak · 2 shared papers, 2023–2024 · strength 0.31
  17. Erqi Liu Pollom · 2 shared papers, 2014–2026 · strength 0.28
  18. M. Usman Ahmad · 1 shared paper, 2026 · strength 0.24
  19. Gregory M. Heestand · 1 shared paper, 2026 · strength 0.24
  20. Albert C. Koong · 4 shared papers, 2011–2016 · strength 0.14
  21. Jee-Soo Lee · 1 shared paper, 2019 · strength 0.12
  22. Young Kyung Lee · 1 shared paper, 2019 · strength 0.12
  23. Sung Sup Park · 1 shared paper, 2019 · strength 0.12
  24. Stefanie S. Jeffrey · 1 shared paper, 2019 · strength 0.12
  25. James M. Ford · 3 shared papers, 2011–2014 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.